ResQ Pharma, Inc.

ResQ Pharma, Inc. specializes in developing advanced medical solutions for toxicological emergencies, focusing on drug toxicity and overdose treatments. Their innovative approach addresses critical healthcare needs in emergency medicine. Founded in 2010, ResQ Pharma, Inc.

is based in Chicago, US. The company focuses on creating medical solutions for drug toxicity and overdose, primarily through its proprietary lipid emulsion product. In September 2016, ResQ Pharma raised USD 0. 73 million in SEED funding, bringing its total seed financing to USD 1.

05 million. The company has completed 2 deals since its inception. Lipid Rescue provides advanced medical solutions targeted at toxicological emergencies, with a proprietary lipid emulsion designed to treat drug toxicity cases, such as local anesthetic systemic toxicity (LAST). This emulsion aids in binding lipophilic drugs for elimination from the body, restoring cardiovascular stability.

Its products are used in clinical settings by healthcare professionals, particularly in emergency medicine and anesthesiology, and are available to hospitals, clinics, and emergency medical services across North America, Europe, and select regions in Asia. ResQ Pharma generates revenue through direct sales of its lipid emulsion products to healthcare institutions, operating on a B2B model. Clients place bulk orders through established procurement channels, facilitating a consistent supply to hospitals and clinics. Pricing is based on unit costs per vial, supporting efficient budgeting for emergency protocols.

Partnerships with medical wholesalers further expand distribution across various markets, ensuring availability for healthcare providers in critical situations. ResQ Pharma plans to utilize the recent SEED financing of USD 0. 73 million, raised in September 2016, to support the development of new products and expand its market reach. The company is focused on launching upcoming innovative solutions aimed at enhancing treatment options for toxicological emergencies.

Additionally, it aims to enter new geographical markets, specifically targeting Europe and select Asian regions by 2024, to broaden its client base and improve service delivery in emergency medical care.